Landmark Study Finds Limited Survival Benefit from Routine Hormone Therapy with Postoperative Radiation for Prostate Cancer

Research team led by UH Seidman Cancer Center and UCLA published results in The Lancet; Presented at the American Society of Clinical Oncology Genitourinary Symposium

• Study shows adding hormone therapy to postoperative radiotherapy for recurrent prostate cancer does not significantly improve overall survival for most men treated early after prostatectomy.
• Findings come from the first individual patient data meta-analysis addressing this question, analyzing more than 6,000 patients across six randomized phase III trials.
• The study represents the most comprehensive evaluation to date of whether hormone therapy should routinely accompany radiation after prostate surgery.
• Highlights importance of tailoring therapy based on individual risk factors — particularly PSA levels at the time of radiation.
• Underscores urgent need for predictive biomarkers that can identify which patients truly benefit from hormone therapy in the postoperative setting.

CLEVELAND – A major, international study published in The Lancet and presented as a plenary presentation today at the American Society of Clinical Oncology Genitourinary Symposium in San Fransico, reports that adding hormone therapy to postoperative radiotherapy for recurrent prostate cancer does not significantly improve overall survival for most men treated early after prostatectomy.

The findings come from the first individual patient data meta-analysis addressing this question, analyzing more than 6,000 patients across six randomized phase III trials.

The study, conducted through the MARCAP Consortium (Meta-Analysis of Randomized Trials in Cancer of the Prostate), represents the most comprehensive evaluation to date of whether hormone therapy should routinely accompany radiation after prostate surgery.

The study was led by co-principal investigators, Daniel E. Spratt, MD, of University Hospitals Seidman Cancer Center, and Amar U. Kishan, MD, of UCLA Health.

Addressing a Long-Standing Clinical Question

Hormone therapy has been proven to improve survival when combined with radiation in men treated for intact prostate cancer. However, whether the same benefit applies when radiation is delivered after prostatectomy — a common treatment for recurrent disease — has remained uncertain for decades.

Previous randomized trials yielded mixed conclusions. Some suggested benefit, others did not. To answer this question definitively, investigators pooled individual data from 6,057 patients with nearly a decade of follow-up.

Key Findings

Across all patients, the study found that adding hormone therapy to postoperative radiotherapy did not significantly improve overall survival. Ten-year overall survival was nearly identical:

• 83.6% with radiation alone
• 84.3% with radiation plus hormone therapy

Importantly, outcomes varied based on prostate-specific antigen (PSA) levels at the time radiation was delivered:

• Men treated early (PSA ≤0.5 ng/mL) showed no meaningful survival benefit from adding hormone therapy.
• Potential survival benefit emerged primarily in men treated later, particularly when PSA exceeded approximately 1.6–2.0 ng/mL.
• Differences between short-term and long-term hormone therapy were smaller than expected.

While hormone therapy improved metastasis-free survival, the magnitude of benefit was modest and unlikely to translate into meaningful overall survival gains for most patients treated early.

Implications for Patients and Clinicians

Hormone therapy can carry significant side effects, including fatigue, metabolic changes, cardiovascular risks, and effects on sexual health. These findings suggest that many men treated early after surgery may safely avoid additional systemic therapy without compromising survival.

“This is the strongest level of evidence we’ve ever had addressing this question,” said the senior author Dr. Spratt, Vincent K. Smith Chair of Radiation Oncology, UH Seidman Cancer Center, Associate Chief Scientific Officer, UH Cleveland Medical Center, and Professor of Radiation Oncology, Case Western Reserve University School of Medicine. “For men treated early at low PSA levels, the routine addition of hormone therapy does not meaningfully improve overall survival. That has major implications for quality of life and treatment personalization.”

“Hormone therapy is not benign,” Dr. Spratt added. “If we can safely spare men unnecessary treatment while maintaining excellent cancer outcomes, that is a significant step forward in precision oncology.”

Moving Toward More Personalized Care

The study highlights the importance of tailoring therapy based on individual risk factors — particularly PSA levels at the time of radiation.

It also underscores an urgent need for predictive biomarkers that can identify which patients truly benefit from hormone therapy in the postoperative setting. Ongoing clinical trials are exploring genomic and molecular tools to refine treatment decisions further.

“The era of one-size-fits-all treatment is ending,” Dr. Spratt said. “Our goal is to deliver the right therapy, to the right patient, at the right time — and sometimes that means safely doing less.”